pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

908 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1199Endpoints912BioPharma Dive351BioSpace327Fierce Biotech307onclive165raps109globenewswire health73fda recalls
therapy area
allOncology7879Rare Disease1904Cardiology1810Immunology1522Hematology1339Pulmonology1222Vaccines
  • Key AUA 2026 abstracts to watch: immunotherapy for NMIBC and radioligand therapy for mHSPC
    The American Urological Association 2026 meeting will feature several highly anticipated abstracts. Experts say immunotherapy for non‑muscle‑invasive bladder cancer is a major focus, reflecting gr…
    onclive · 3mo agoNeutral↗ source
  • Experts clarify differences between glioblastoma and diffuse midline glioma under 2021 WHO classification
    In the opening episode of their series, Dr. Shonka and Dr. Chong introduce a discussion about two distinct diseases that both carry the name glioma. They explain that glioblastoma and diffuse midl…
    onclive · 3mo agoNeutral↗ source
← prev
page 32 of 37
next →
70
fda medwatch61
fda press38
1213
Psychiatry & CNS877
Ophthalmology515
Pain489
Endocrinology & Metabolism486
Infectious Disease451
Case Introduction Highlights ctDNA as Emerging Risk Factor
The article presents a case introduction that focuses on circulating tumor DNA (ctDNA) as a potential emerging risk factor. It outlines the relevance of ctDNA in assessing disease risk, emphasizin…
onclive · 3mo agoNeutral↗ source
  • MRI Features That Suggest Diffuse Midline Glioma Highlighted in Expert Discussion
    In a recent educational segment, Dr. Chong introduced the clinical scenario where patients with suspected brain tumors are first evaluated with imaging before tissue sampling. He then asked Dr. Sh…
    onclive · 3mo agoNeutral↗ source
  • Article on clinical implementation and surveillance provides no details
    The source article titled "Clinical Implementation and Surveillance Strategies" contains no summary or body text. No specific information about implementation methods, surveillance approaches, or…
    onclive · 3mo agoNeutral↗ source
  • FDA approves oral decitabine/cedazuridine plus venetoclax for older AML patients unable to tolerate intensive chemo
    The FDA has approved the oral combination of decitabine/cedazuridine (Inqovi) with venetoclax (Venclexta) for adults with newly diagnosed acute myeloid leukemia who are at least 75 years old or hav…
    onclive · 4mo agoApprovalPositive↗ source
  • FDA approves all-oral decitabine/cedazuridine plus venetoclax for older or unfit AML patients
    The FDA has granted approval for the combination of decitabine and cedazuridine (Inqovi) with venetoclax (Venclexta) to treat newly diagnosed acute myeloid leukemia in adults who are at least 75 ye…
    onclive · 4mo agoApprovalPositive↗ source
  • FDA approves brexu-cel for adult relapsed/refractory mantle cell lymphoma
    The U.S. Food and Drug Administration has granted approval for brexu-cel as a treatment option for adult patients with relapsed or refractory mantle cell lymphoma. Dr. Luhua (Michael) Wang discuss…
    onclive · 4mo agoApprovalPositive↗ source
  • FDA grants accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma
    The U.S. Food and Drug Administration has granted accelerated approval to sonrotoclax (brand name Beqalzi) for adult patients with relapsed or refractory mantle cell lymphoma who have received at l…
    onclive · 4mo agoApprovalPositive↗ source
  • Pirtobrutinib Extends Progression-Free Survival to 14 Months in BTK-Inhibitor-Pretreated CLL Patients
    The phase 3 CLL-321 trial enrolled patients whose disease had progressed after prior covalent BTK inhibitor therapy. Participants were randomly assigned to receive pirtobrutinib or the investigator…
    onclive · 4mo agoPositive readoutPositive↗ source
  • FDA expands pirtobrutinib use to second-line CLL after covalent BTKi failure, broadening treatment options
    The BRUIN CLL-321 phase 3 trial provided the data that led the FDA to approve pirtobrutinib for patients whose chronic lymphocytic leukemia has progressed after a covalent BTK inhibitor. This marks…
    onclive · 4mo agoApprovalPositive↗ source
  • Oral SERDs show promise in hormone-receptor positive breast cancer, offering alternative to injections
    Oral selective estrogen receptor degraders (SERDs) are being positioned as a new approach for metastatic hormone-receptor positive breast cancer because they can break down the estrogen receptor an…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Retifanlimab plus chemo improves progression-free survival in first-line SCAC trial
    Topline results from the PODIUM-303 study show that adding the PD-1 inhibitor retifanlimab to carboplatin and paclitaxel improves outcomes for patients with squamous cell carcinoma of the anal cana…
    onclive · 3mo agoPositive readoutPositive↗ source
  • MD Anderson expert highlights impact of WHO’s updated AML diagnostic criteria on patient care
    Dr Sanam Loghavi, an associate professor and medical director at MD Anderson Cancer Center, discussed the recently revised WHO diagnostic criteria for acute myeloid leukemia. She emphasized that a…
    onclive · 3mo agoPositive↗ source
  • Tirabrutinib and CAR T-cell therapy show promise for relapsed/refractory primary CNS lymphoma
    Experts highlighted emerging data on tirabrutinib and CAR T-cell therapy as potential new options for patients with relapsed or refractory primary central nervous system lymphoma. CAR T-cell thera…
    onclive · 4mo agoRegulatoryPositive↗ source
  • Experts discuss combination and sequencing approaches for radiopharmaceuticals in advanced prostate cancer
    Dr. Pedro Barata and Dr. Johann De Bono review the current questions surrounding how best to combine and sequence radiopharmaceutical therapies for patients with metastatic castration‑resistant pro…
    onclive · 4mo agoNeutral↗ source
  • UCSF receives $100 million gift to fund capital projects, cancer research and hospital modernization
    Longtime supporters Kathy Chiao and Kenneth Hao have pledged $100 million to the University of California, San Francisco. The commitment is intended to address the university’s most urgent capital…
    onclive · 4mo agoDealPositive↗ source
  • Biomarker testing guides endometrial cancer treatment and highlights gaps in second-line options after immunotherapy
    The discussion highlighted that performing biomarker testing at diagnosis is now standard for endometrial cancer, helping decide between targeted therapies and immunotherapy. The experts described…
    onclive · 4mo agoNeutral↗ source
  • Alpha-emitting radiopharmaceuticals gain attention in metastatic castration-resistant prostate cancer
    Dr. Johann De Bono and Dr. Pedro Barata reviewed the current landscape of alpha-emitting radiopharmaceuticals for patients with metastatic castration-resistant prostate cancer (mCRPC). They highli…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Experts discuss the evolving role of radiopharmaceuticals in advanced prostate cancer
    Dr. Pedro Barata and Dr. Johann de Bono wrapped up a series on metastatic castration-resistant prostate cancer by looking ahead to how radiopharmaceutical treatments may shape care. They highlight…
    onclive · 4mo agoPositive↗ source
  • Experts highlight growing complexity of personalized therapy choices for metastatic castration-resistant prostate cancer
    Dr. Johann De Bono and Dr. Pedro Barata discuss how treatment decisions for metastatic castration-resistant prostate cancer are becoming more intricate as new radiopharmaceuticals and targeted agen…
    onclive · 4mo agoNeutral↗ source
  • Experts outline emerging radiopharmaceutical approaches for metastatic castration-resistant prostate cancer
    Dr. Pedro Barata and Dr. Johann De Bono discuss the next steps for radiopharmaceutical therapies aimed at metastatic castration-resistant prostate cancer, highlighting how these agents could reshap…
    onclive · 4mo agoNeutral↗ source
  • Experts discuss sequencing and patient selection for radiopharmaceuticals in advanced prostate cancer
    Dr. Johann De Bono and Dr. Pedro Barata discuss how treatment sequencing is evolving for radiopharmaceuticals in metastatic castration-resistant prostate cancer. They highlight the need to match p…
    onclive · 4mo agoNeutral↗ source
  • Choosing the Right Radiopharmaceuticals for Advanced Prostate Cancer
    Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics affect the use of radiopharmaceuticals in metastatic castration‑resistant prostate cancer (mCRPC).…
    onclive · 4mo agoNeutral↗ source
  • Experts review expanding role of radiopharmaceuticals in metastatic castration-resistant prostate cancer
    Dr. Pedro Barata and Dr. Johann De Bono open a discussion on the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC). They describe how these agents ar…
    onclive · 4mo agoNeutral↗ source